These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 9435414)

  • 1. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
    Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
    Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
    Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey.
    Yoshida K; Aizawa Y; Kaise N; Fukazawa H; Kiso Y; Sayama N; Mori K; Hori H; Abe K
    J Endocrinol Invest; 1996 Nov; 19(10):682-6. PubMed ID: 9007700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
    Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
    Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves' disease.
    Yoshida K; Aizawa Y; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Nakazato N; Tani J; Abe K
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):17-22. PubMed ID: 9509063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid response, especially to thyrotropin-binding inhibitory immunoglobulins, in euthyroid relatives of patients with Graves' disease: a clinical follow-up.
    Tamai H; Kasagi K; Morita T; Hidaka A; Kuma K; Konishi J; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1990 Jul; 71(1):210-5. PubMed ID: 1973421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.
    Michelangeli VP; Poon C; Topliss DJ; Colman PG
    Thyroid; 1995 Jun; 5(3):171-6. PubMed ID: 7580264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
    Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
    Korean J Intern Med; 1990 Jan; 5(1):51-7. PubMed ID: 1980206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
    McLachlan SM; Rapoport B
    Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.